MiniMed Group (NASDAQ:MMED) Stock Price Expected to Rise, Morgan Stanley Analyst Says

MiniMed Group (NASDAQ:MMED) had its target price lifted by investment analysts at Morgan Stanley from $19.00 to $21.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential downside of 10.81% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. UBS Group boosted their price objective on MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Wednesday. BTIG Research lifted their price target on MiniMed Group from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday. Citigroup upped their price target on MiniMed Group from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday. Benchmark reissued a “buy” rating on shares of MiniMed Group in a research report on Thursday, June 4th. Finally, Bank of America raised their price objective on shares of MiniMed Group from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Wednesday. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $23.77.

MiniMed Group Price Performance

NASDAQ:MMED traded down $0.21 during midday trading on Thursday, reaching $23.55. The stock had a trading volume of 137,369 shares, compared to its average volume of 1,107,661. The firm has a market capitalization of $6.62 billion and a PE ratio of -34.79. MiniMed Group has a 1-year low of $10.65 and a 1-year high of $24.43. The business has a fifty day moving average price of $17.84.

MiniMed Group (NASDAQ:MMED) last released its quarterly earnings results on Wednesday, June 3rd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.46). The business had revenue of $837.00 million for the quarter. The company’s quarterly revenue was up 15.6% on a year-over-year basis. As a group, equities research analysts expect that MiniMed Group will post 0.66 EPS for the current year.

Hedge Funds Weigh In On MiniMed Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in MMED. California State Teachers Retirement System acquired a new stake in shares of MiniMed Group during the 2nd quarter worth approximately $89,000. Legal & General Group Plc bought a new position in MiniMed Group in the second quarter worth $91,000. The Manufacturers Life Insurance Company acquired a new stake in MiniMed Group during the second quarter worth $185,000. Punch & Associates Investment Management Inc. acquired a new stake in MiniMed Group during the second quarter worth $292,000. Finally, Washington Growth Strategies LLC bought a new stake in MiniMed Group in the 2nd quarter valued at $397,000.

Key Stories Impacting MiniMed Group

Here are the key news stories impacting MiniMed Group this week:

• Positive Sentiment: MiniMed reported fiscal Q1 2027 sales growth of approximately 17%, while earnings per share exceeded analyst expectations. The results helped support renewed optimism about the company’s operating momentum. MiniMed Group Q1 2027 Deep Dive: EPS Beats, Revenue Up 17%
• Positive Sentiment: Several firms raised their price targets following the quarterly report. UBS lifted its target to $28 from $25, Bank of America raised its target to $28 from $24, and BTIG increased its target to $28 from $25; all maintained or initiated bullish “buy” ratings. MiniMed Group Stock Price Expected to Rise, BTIG Research Analyst Says
• Positive Sentiment: Mizuho, Wells Fargo and Citigroup each raised their targets to $26, with ratings of “outperform,” “overweight” and “buy,” respectively. The revisions indicate broader analyst confidence after the sales performance. Analysts Boost Forecasts Following Q1 Sales Results
• Neutral Sentiment: The overall broker consensus target is $21.62, below the reference price of $23.76, although the latest individual target increases are substantially higher. This divergence suggests that older estimates may not yet reflect the latest earnings update. MiniMed Group Receives Consensus Target Price from Brokerages

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.